- en: <!--yml
  id: totrans-0
  prefs: []
  type: TYPE_NORMAL
  zh: <!--yml
- en: 'category: 未分类'
  id: totrans-1
  prefs: []
  type: TYPE_NORMAL
  zh: 'category: 未分类'
- en: 'date: 2024-05-18 03:43:34'
  id: totrans-2
  prefs: []
  type: TYPE_NORMAL
  zh: 'date: 2024-05-18 03:43:34'
- en: -->
  id: totrans-3
  prefs: []
  type: TYPE_NORMAL
  zh: -->
- en: 'Humble Student of the Markets: A biotech bubble? Maybe not!'
  id: totrans-4
  prefs:
  - PREF_H1
  type: TYPE_NORMAL
  zh: 'Humble Student of the Markets: 生物技术泡沫？也许不是！'
- en: 来源：[https://humblestudentofthemarkets.blogspot.com/2014/02/a-biotech-bubble-think-again.html#0001-01-01](https://humblestudentofthemarkets.blogspot.com/2014/02/a-biotech-bubble-think-again.html#0001-01-01)
  id: totrans-5
  prefs:
  - PREF_BQ
  type: TYPE_NORMAL
  zh: 来源：[https://humblestudentofthemarkets.blogspot.com/2014/02/a-biotech-bubble-think-again.html#0001-01-01](https://humblestudentofthemarkets.blogspot.com/2014/02/a-biotech-bubble-think-again.html#0001-01-01)
- en: The biotechnology sector has been on a tear for the past few years. A glance
    at the biotech ETF (IBB) shows that this group (bottom panel) has been steadily
    advancing since the stock market bottomed in 2009\. It decisively broke out to
    new all-time highs in late 2010\. By contrast, the SPX (top panel) didn't exceed
    its old highs until three years later in 2013.
  id: totrans-6
  prefs: []
  type: TYPE_NORMAL
  zh: 过去几年，生物技术行业一直在高速发展。通过观察生物技术ETF（IBB），可以看出这个群体（底部面板）自2009年股市触底以来一直稳步增长，并于2010年底决定性地突破了创纪录的新高。相比之下，SPX（顶部面板）直到2013年三年后才超过其旧高。
- en: In a recent article, the
  id: totrans-7
  prefs: []
  type: TYPE_NORMAL
  zh: 最近一篇文章中，
- en: '[FT](http://www.ft.com/intl/cms/s/0/27482366-9032-11e3-a776-00144feab7de.html#axzz2tjsr0Ncz)'
  id: totrans-8
  prefs: []
  type: TYPE_NORMAL
  zh: '[FT](http://www.ft.com/intl/cms/s/0/27482366-9032-11e3-a776-00144feab7de.html#axzz2tjsr0Ncz)'
- en: 'warned of a growing bubble in this sector. The appearance of rising IPO volumes
    and lower quality (earlier stage company) IPOs are key warning signs:'
  id: totrans-9
  prefs: []
  type: TYPE_NORMAL
  zh: 警告称这个行业的泡沫不断增长。不断上升的IPO数量和较低质量（较早期的公司阶段）的IPO是关键的警告信号：
- en: The fastest start to a year for US biotech initial public offerings is stoking
    fears of a bubble amid concerns investors are taking risks on companies at the
    earliest stage of medical research.
  id: totrans-10
  prefs:
  - PREF_BQ
  type: TYPE_NORMAL
  zh: 美国生物技术公司首次公开发行（IPO）今年的最快开始引发了人们对泡沫的恐惧，因为投资者对医学研究的早期阶段的公司冒险投资。
- en: ''
  id: totrans-11
  prefs:
  - PREF_BQ
  type: TYPE_NORMAL
- en: Another eight biotech companies raised a combined $502m in US listings last
    week, setting a weekly record for the sector and continuing a boom that has seen
    the Nasdaq biotech index rise more than two-thirds in the past year.
  id: totrans-12
  prefs:
  - PREF_BQ
  type: TYPE_NORMAL
  zh: 另外八家生物技术公司上周在美国上市共募集了5.02亿美元，创下了该行业的周记录，继续了一年多以来拜访的繁荣，纳斯达克生物技术指数已上涨了超过三分之二。
- en: ''
  id: totrans-13
  prefs:
  - PREF_BQ
  type: TYPE_NORMAL
- en: However, fears of overheating are growing as companies come to market at an
    early stage of drug development when failures are high – and in one case without
    the usual restrictions that bar existing owners from making a quick profit on
    IPOs.
  id: totrans-14
  prefs:
  - PREF_BQ
  type: TYPE_NORMAL
  zh: 然而，随着公司在药物研发的早期阶段上市，风险逐渐增加 – 有时甚至没有传统的限制，禁止现有所有者在IPO上快速获利。
- en: The Economist (via
  id: totrans-15
  prefs: []
  type: TYPE_NORMAL
  zh: 《经济学人》（经由
- en: '[Business Insider](http://www.businessinsider.com/why-the-latest-biotech-boom-may-not-be-followed-by-another-bust-2014-2)'
  id: totrans-16
  prefs: []
  type: TYPE_NORMAL
  zh: '[Business Insider](http://www.businessinsider.com/why-the-latest-biotech-boom-may-not-be-followed-by-another-bust-2014-2)'
- en: ') also pointed to rising IPO volumes as a possible risk, but suggested that
    there are reasons to be more sanguine about the current biotech boom. First, the
    business model for many biotech companies has changed:'
  id: totrans-17
  prefs: []
  type: TYPE_NORMAL
  zh: ）还指出了不断上升的IPO数量可能构成的风险，但也提出了有关目前生物技术繁荣更加乐观的理由。首先，许多生物技术公司的商业模式已发生变化：
- en: There are several reasons to hope that even if the current share-price and IPO
    frenzy subsides, biotech firms will continue to prosper. First, many smaller firms
    have become the research engines for bigger ones, explains Kevin Starr of Third
    Rock, a venture-capital firm.
  id: totrans-18
  prefs:
  - PREF_BQ
  type: TYPE_NORMAL
  zh: 有几个原因使人们希望即使目前的股价和IPO的狂热消退，生物技术公司仍将继续繁荣。首先，很多小公司已成为更大公司的研究引擎，风险投资公司Third Rock的Kevin
    Starr解释道。
- en: ''
  id: totrans-19
  prefs:
  - PREF_BQ
  type: TYPE_NORMAL
- en: For example Sanofi, a French pharmaceutical giant, now depends on Regeneron,
    an American biotech company, to help drive its growth. This year alone, Sanofi
    will pump about $1 billion into Regeneron’s research programme. The goal is not
    to "Sanofise" Regeneron or any other partner, says Christopher Viehbacher, Sanofi’s
    chief executive. Rather, it is to combine Regeneron’s capabilities in researching
    new treatments with Sanofi’s skill in bringing them to market.
  id: totrans-20
  prefs:
  - PREF_BQ
  type: TYPE_NORMAL
  zh: 例如，法国制药巨头赛诺菲现在依赖于美国生物技术公司再生元，帮助推动其增长。仅今年，赛诺菲将为再生元的研究计划投入约10亿美元。赛诺菲首席执行官克里斯托弗·V说，目标并非使再生元或任何其他合作伙伴成为“赛诺菲”，而是将再生元的研究新药的能力与赛诺菲在市场化新药方面的能力相结合。
- en: ''
  id: totrans-21
  prefs:
  - PREF_BQ
  type: TYPE_NORMAL
- en: Celgene, one of America’s larger biotech firms, has a similar "distributed model"
    of research. It helps finance the scientific work at smaller companies, then usually
    takes over a drug’s development as it moves into clinical trials. Besides being
    costly, these require expertise that younger, smaller firms often lack.
  id: totrans-22
  prefs:
  - PREF_BQ
  type: TYPE_NORMAL
  zh: Celgene，美国较大的生物科技公司之一，也采用类似的“分散式模式”进行研究。它帮助资助较小公司的科学工作，然后通常在药物进入临床试验阶段时接管其开发工作。除了成本高昂外，这些工作还需要年轻的小公司往往缺乏的专业知识。
- en: 'As well, we are starting to see the benefits from the human genome project,
    which holds the promise of truly disruptive life extension technologies - and
    immense cash flow:'
  id: totrans-23
  prefs: []
  type: TYPE_NORMAL
  zh: 此外，我们开始看到人类基因组计划带来的好处，这计划有望带来真正颠覆性的寿命延长技术和巨大的现金流：
- en: Second--and more important--firms are at last starting to reap the rewards of
    studying the human genome. As researchers illuminate the underlying genetic causes
    of a disease, they open up new routes to developing treatments.
  id: totrans-24
  prefs:
  - PREF_BQ
  type: TYPE_NORMAL
  zh: 其次——更重要的是——公司最终开始从研究人类基因组中获得回报。随着研究人员阐明疾病的潜在遗传原因，他们打开了开发治疗方法的新途径。
- en: ''
  id: totrans-25
  prefs:
  - PREF_BQ
  type: TYPE_NORMAL
- en: For example, Vertex has a drug to treat a subset of patients with cystic fibrosis,
    thanks to a better understanding of the faulty gene that causes it. Bluebird bio,
    one of Celgene’s small partner firms, which Third Rock also financed, is working
    on a treatment for sickle-cell disease that inserts into the patient’s blood cells
    a properly functioning version of the faulty gene that causes the inherited ailment.
  id: totrans-26
  prefs:
  - PREF_BQ
  type: TYPE_NORMAL
  zh: 例如，Vertex生物科技公司已经开发出了一种用于治疗囊性纤维化的药物，这归功于对导致其疾病的缺陷基因的更好了解。作为Celgene的一个小合作伙伴公司，Third
    Rock也资助了Bluebird生物科技公司，该公司正在研究一种治疗镰状细胞病的治疗方法，将一个功能正常的基因插入患者的血细胞中，以取代导致遗传疾病的缺陷基因。
- en: ''
  id: totrans-27
  prefs:
  - PREF_BQ
  type: TYPE_NORMAL
- en: Advances in genomics are making clinical trials smaller and cheaper, since it
    is now easier to identify which patients have the specific genetic trait that
    a new drug is aimed at. This makes it more worthwhile to research diseases that
    are rare, and those that have so far proved intractable. The FDA gives special
    consideration to drugs that treat such ailments, so companies can expect a speedier
    path to approval.
  id: totrans-28
  prefs:
  - PREF_BQ
  type: TYPE_NORMAL
  zh: 基因组学的进步使临床试验变得更小、更便宜，因为现在更容易识别哪些患者具有新药物针对的特定基因特征。这使得值得研究那些罕见疾病和迄今为止难以治愈的疾病变得更有价值。FDA对治疗这类疾病的药物特别重视，因此公司可以期望获得更快的审批路径。
- en: From a technician's viewpoint, the surge in this group may be just starting.
    A 15 year chart of the relative returns of IBB against SPY shows that the biotech
    group only recently staged a relative breakout out of a long multi-year base lasting
    over a decade.
  id: totrans-29
  prefs: []
  type: TYPE_NORMAL
  zh: 从技术员的角度来看，该组织的激增可能刚刚开始。IBB与SPY之间相对回报的15年图表显示，生物科技组织最近才从持续了十多年的长期基地中相对突破出来。
- en: This technical pattern suggests that biotechnology stocks could be the next
    moonshot winner - the next darling group that the momentum crowd embraces and
    outperformance could go on for much longer than anyone imagines. We may need comments
    like "valuations don't matter" and the emergence some truly *ahem* creative valuation
    techniques, such as the price to eyeballs metric of the internet era, before the
    bubble pops.
  id: totrans-30
  prefs: []
  type: TYPE_NORMAL
  zh: 这种技术模式表明，生物科技股票可能成为下一个大赢家——动能群体拥抱和超额表现可能会持续时间比任何人想象的都要长。我们可能需要像“估值无关紧要”这样的评论，以及一些真正
    *啊嗯* 创造性的估值技术，如互联网时代的眼球价格指标，才能产生泡沫破裂。
- en: Obviously this call is highly speculative. If I am right, shorting biotechs
    now could be like shorting technology when Netscape did its IPO because the valuations
    were overly ambitious.
  id: totrans-31
  prefs: []
  type: TYPE_NORMAL
  zh: 显然，这种判断是高度投机的。如果我是对的，目前做生物科技的空头可能就像在网景进行首次公开募股时做技术空头一样，因为估值过于雄心勃勃。
- en: '*Cam Hui is a portfolio manager at [Qwest Investment Fund Management Ltd.](http://www.qwestfunds.com/)
    (“Qwest”). The opinions and any recommendations expressed in the blog are those
    of the author and do not reflect the opinions and recommendations of Qwest. Qwest
    reviews Mr. Hui’s blog to ensure it is connected with Mr. Hui’s obligation to
    deal fairly, honestly and in good faith with the blog’s readers.”'
  id: totrans-32
  prefs: []
  type: TYPE_NORMAL
  zh: '*Cam Hui是[Qwest Investment Fund Management Ltd.](http://www.qwestfunds.com/)（“Qwest”）的投资组合经理。在博客中表达的任何观点和建议都是作者个人观点，不代表Qwest的观点和建议。Qwest会审核梅先生的博客，以确保其与梅先生对读者的公平、诚实和善意的义务相关联。”'
- en: None of the information or opinions expressed in this blog constitutes a solicitation
    for the purchase or sale of any security or other instrument. Nothing in this
    blog constitutes investment advice and any recommendations that may be contained
    herein have not been based upon a consideration of the investment objectives,
    financial situation or particular needs of any specific recipient. Any purchase
    or sale activity in any securities or other instrument should be based upon your
    own analysis and conclusions. Past performance is not indicative of future results.
    Either Qwest or I may hold or control long or short positions in the securities
    or instruments mentioned.*
  id: totrans-33
  prefs: []
  type: TYPE_NORMAL
  zh: 本博客中的任何信息或意见均不构成对任何证券或其他工具的购买或销售的征求。本博客中的任何内容均不构成投资建议，可能包含的任何建议均未基于对任何特定接收者的投资目标、财务状况或特定需求的考虑。任何证券或其他工具的买卖活动应基于您自己的分析和结论。过去的业绩不预示未来结果。Qwest或我可能持有或控制所提到的证券或工具的多头或空头头寸。
